Merck & Co., Inc. MRK
Set alert
At close
Pre-market · Nov 2, 5:24 AM ET
- YTD
- +42.05%
- 1 year
- +73.90%
- Open
- 149.55
- Prev close
- 146.33
- Mkt cap
- 368.89B
- Vol
- 12.30M
- Avg vol
- 10.36M
- EPS
- 0.99
- P/E
- 151.03
- Div yield
- 2.32%
More statistics
- Low
- 147.43
- High
- 151.35
- Forward P/E
- 16.19
- Beta
- 0.00
- Short ratio
- 2.68
- Inst. own
- 82.88%
- Dividend
- 3.40
- Ex-div date
- Sep 14, 2026
- Earnings
- Feb 2, 2027
- 50-d avg
- 146.85
- 200-d avg
- 126.52
- 1y target
- 159.60
5D chart
Events in this range
- Oct 26, 2026Rating: Barclays · Overweight → Overweight
- Oct 29, 2026Earnings: 2.49; estimate 2.09; surprise 19.14%
- Oct 30, 2026Rating: Guggenheim · Buy → Buy
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
Signals (143)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| RSI: Oversold | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| RSI: Oversold | Oct 26, 12:00 PM | 6 days ago |
| RSI: Oversold | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:30 AM | 6 days ago |
News
15 hours ago youtube.com
Moderna, Merck eye FDA approval for promising cancer vaccine
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.' #fox #foxbusiness…
2 days ago benzinga.com
Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
2 days ago defenseworld.net
Founders Financial Securities LLC Sells 3,449 Shares of Merck & Co., Inc. $MRK
Founders Financial Securities LLC lowered its position in shares of Merck and Co., Inc. (NYSE: MRK) by 17.9% in the undefined quarter, according to its most recent disclosure with the Securities and…
2 days ago fool.com
Why Merck Stock Flew Higher on Friday
The company easily beat analyst estimates for both revenue and net income. Market players didn't seem overly worried about the future of its top drug.
-
2 days ago benzinga.com
JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175
JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $165 to $175.
2 days ago benzinga.com
Merck One of Top Large-Cap Biopharma Picks-Analyst
Merck & Co. Inc. (NYSE:MRK) shares were trading higher on Friday on a continued rally on better-than-expected third-quarter earnings and upbeat fiscal 2026 guidance.
2 days ago benzinga.com
Merck One of Top Large-Cap Biopharma Picks-Analyst
Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
-
2 days ago benzinga.com
RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $140
RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $145 to $140.
2 days ago 247wallst.com
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
2 days ago 247wallst.com
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron…
2 days ago zacks.com
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
MRK raises its 2026 outlook as KEYTRUDA demand, newer medicines and oncology pipeline breakthroughs support growth despite looming patent and generic pressures.
2 days ago benzinga.com
Defensives Lead Sectors In Friday Trading As Growth Trails
Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
2 days ago businesswire.com
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy")…
-
2 days ago benzinga.com
Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $171
Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.
2 days ago businesswire.com
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today…
2 days ago marketbeat.com
Merck & Co., Inc. Q3 Earnings Call Highlights
Merck & Co., Inc. NYSE: MRK reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset…
3 days ago businesswire.com
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is…
3 days ago fool.com
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction
Newer drugs are scaling fast enough to offset generic losses. Merck's third-quarter sales rose 5% to about $18.1 billion, but roughly $550 million of that came from the timing of customer purchases,…
3 days ago seekingalpha.com
Merck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript
Merck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript
3 days ago benzinga.com
Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027
Merck & Co. Inc. (NYSE:MRK) stock edged higher Thursday after the drugmaker reported third-quarter results that topped Wall Street revenue expectations and upbeat financial guidance.
3 days ago benzinga.com
Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027
Merck beats Q3 estimates and raises 2026 guidance as Keytruda and Winrevair propel quarterly sales past Wall Street expectations.
3 days ago zacks.com
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
3 days ago zacks.com
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up
Merck's Q3 earnings and sales beat estimates as Keytruda and newer products drive growth, prompting the company to raise its 2026 earnings outlook.
3 days ago benzinga.com
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
3 days ago 247wallst.com
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.
3 days ago benzinga.com
8 Of 11 Sectors Rise Thursday As Defensives Lead
Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…
3 days ago seekingalpha.com
Merck: A Strong Quarter, But It's Time To Take A Step Back
In the third quarter, Merck & Co., Inc.'s revenue grew 8.9% QoQ. Sales of Keytruda+Keytruda Qlex, its PD-1 immune checkpoint inhibitors, reached $8.1 billion, up 5.6% YoY and 2.8% QoQ. Winrevair, its…
3 days ago zacks.com
Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates
Merck (MRK) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.58 per share a year ago.
3 days ago seekingalpha.com
Building A 7%-Yielding Dividend Growth Portfolio With SCHD As Its Core Holding
SCHD is one of the best dividend growth ETFs available, but its modest 3% yield and several important diversification gaps make it insufficient for many income-focused retirees. I explain how…
3 days ago wsj.com
Merck Revenue Up on Keytruda, Winrevair Growth
Third-quarter profit came in at $5.07 billion, or $2.04 a share, compared with $5.79 billion, or $2.32 a share, a year earlier.
-
3 days ago benzinga.com
Merck & Co Raises FY2026 Adj EPS Guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 Est; Raises FY2026 Sales Guidance from $66.300B-$67.300B to $66.800B-$67.300B vs $67.052B Est
Merck & Co (NYSE:MRK) raises FY2026 Adj EPS guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 analyst estimate. Raises FY2026 sales outlook from $66.300 billion-$67.300 billion to $66.800…
-
3 days ago benzinga.com
Merck Q3 KEYTRUDA/KEYTRUDA QLEX Sales $8.60B (+6% Y/Y)
Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX)KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830…
3 days ago cnbc.com
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted…
-
3 days ago benzinga.com
Merck & Co Q3 Adj. EPS $2.49 Beats $2.08 Estimate, Sales $18.085B Beat $17.313B Estimate
Merck & Co (NYSE:MRK) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.08 by 19.71 percent. This is a 3.49 percent decrease over earnings of $2.58 per…
3 days ago barrons.com
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.
Merck is leaning on newer drugs and the promise of its pipeline assets as a patent cliff looms for its largest revenue driver, Keytruda.
3 days ago businesswire.com
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline.
4 days ago benzinga.com
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
4 days ago benzinga.com
Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings
Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
4 days ago benzinga.com
Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test
Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
4 days ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
4 days ago zacks.com
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)…
4 days ago 247wallst.com
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast.
5 days ago defenseworld.net
Asset Management One Co. Ltd. Purchases 12,550 Shares of Merck & Co., Inc. $MRK
Asset Management One Co. Ltd. raised its position in Merck and Co., Inc. (NYSE: MRK) by 0.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional…
5 days ago 247wallst.com
4 Blue-Chip Dividend Stocks That Could Turn $200,000 Into Annual Retirement Income
Four blue-chip companies have quietly built dividend records spanning decades, but the real story is how a $200,000 split across them generates cash every quarter regardless of what the broader…
5 days ago zacks.com
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
5 days ago marketbeat.com
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.
5 days ago zacks.com
Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?
MRK heads into Q3 earnings with strong Keytruda sales and new drug growth, but declining estimates, Gardasil weakness and looming patent risks cloud its outlook.
6 days ago marketbeat.com
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts
Merck & Co., Inc. NYSE: MRK outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab…
6 days ago seekingalpha.com
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
6 days ago investopedia.com
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.